Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).
Barnadas A, Manso L, de la Piedra C, Meseguer C, Crespo C, Gómez P, Calvo L, Martinez P, Ruiz-Borrego M, Perelló A, Antón A, Codes M, Margelí M, Murias A, Salvador J, Seguí MÁ, de Juan A, Gavilá J, Luque M, Pérez D, Zamora P, Arizcuma A, Chacón JI, Heras L, Martin-Fernández M, Mahillo-Fernández I, Tusquets I. Barnadas A, et al. Among authors: tusquets i. Bone. 2014 Nov;68:32-40. doi: 10.1016/j.bone.2014.07.036. Epub 2014 Aug 7. Bone. 2014. PMID: 25108081
Time-to-progression in breast cancer: a stratification model for clinical trials.
de la Haba-Rodríguez J, Aranda E, Llombart A, Lluch A, Alba E, Munárriz B, Adrover E, Tusquets I, Balil A, Barnadas A, Calvo L, Martín M; Grupo Español de Investigación en Cáncer de Mama (GEICAM). de la Haba-Rodríguez J, et al. Among authors: tusquets i. Breast. 2008 Jun;17(3):239-44. doi: 10.1016/j.breast.2007.09.007. Epub 2007 Nov 26. Breast. 2008. PMID: 18042386
Current controversies in the management of breast cancer.
Tusquets I, García-Estévez L, Adrover E, Calvo L, Alvarez I, García Mata J, Fernández Y, Margueli M, Seguí MA, Muñoz M, Rodríguez C, Rodríguez Lescure A, Colomer R, Gascón P, Martín M, Alba E, Barnadas A, Llombart A, Albanell J, Lluch A. Tusquets I, et al. Clin Transl Oncol. 2010 Apr;12(4):278-86. doi: 10.1007/s12094-010-0504-x. Clin Transl Oncol. 2010. PMID: 20462837 Review.
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Ocaña A, Chacón JI, Calvo L, Antón A, Mansutti M, Albanell J, Martínez MT, Lahuerta A, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chan A, Morales S, Herranz J, Tusquets I, Chiesa M, Caballero R, Valagussa P, Bianchini G, Alba E, Gianni L. Ocaña A, et al. Among authors: tusquets i. Front Oncol. 2022 Feb 11;11:827625. doi: 10.3389/fonc.2021.827625. eCollection 2021. Front Oncol. 2022. PMID: 35223459 Free PMC article.
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I. Gianni L, et al. Among authors: tusquets i. JAMA Oncol. 2018 Mar 1;4(3):302-308. doi: 10.1001/jamaoncol.2017.4612. JAMA Oncol. 2018. PMID: 29327055 Free PMC article. Clinical Trial.
Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain.
Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, Segui MA, Margelí M, Arcusa A, Prat A, Garcia M, Borras JM. Font R, et al. Among authors: tusquets i. Br J Cancer. 2012 Oct 9;107(8):1249-56. doi: 10.1038/bjc.2012.389. Epub 2012 Sep 6. Br J Cancer. 2012. PMID: 22955858 Free PMC article.
Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.
Del Barco S, Colomer R, Calvo L, Tusquets I, Adrover E, Sánchez P, Rifà J, De la Haba J, Virizuela JA. Del Barco S, et al. Among authors: tusquets i. Breast Cancer Res Treat. 2009 Jul;116(2):351-8. doi: 10.1007/s10549-008-0218-8. Epub 2008 Oct 22. Breast Cancer Res Treat. 2009. PMID: 18941891 Clinical Trial.
Finding the right dose of fulvestrant in breast cancer.
Estévez L, Alvarez I, Tusquets I, Seguí MA, Muñoz M, Fernández Y, Lluch A. Estévez L, et al. Among authors: tusquets i. Cancer Treat Rev. 2013 Apr;39(2):136-41. doi: 10.1016/j.ctrv.2012.06.003. Epub 2012 Jul 15. Cancer Treat Rev. 2013. PMID: 22795960 Review.
85 results